A prospective study of multiple protein biomarkers to predict progression in diabetic chronic kidney disease

Nephrology Dialysis Transplantation

Volumn 29, Issue 12, 2014, Pages 2293-2302

  Agarwal, Rajiv ^a   Duffin, Kevin L ^b   Laska, Dennis A ^b   Voelker, James R ^b   Breyer, Matthew D ^b   Mitchell, Peter G ^b  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b ELI LILLY AND COMPANY   (United States)

Author keywords

Albuminuria; Biomarkers; Chronic kidney disease

Indexed keywords

ALBUMIN; BIOLOGICAL MARKER; CREATININE; FIBROBLAST GROWTH FACTOR 23; HEMOGLOBIN A1C; VASCULOTROPIN; PROTEIN;

AGED; ALBUMINURIA; ANGINA PECTORIS; ARTICLE; BLOOD PRESSURE; BODY SIZE; CARBOXY TERMINAL SEQUENCE; CEREBROVASCULAR ACCIDENT; CHRONIC KIDNEY DISEASE; COMORBIDITY; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; CREATININE URINE LEVEL; DIABETIC NEPHROPATHY; DISEASE COURSE; ESTIMATED GLOMERULAR FILTRATION RATE; FEMALE; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HEMOGLOBIN BLOOD LEVEL; HUMAN; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PERIPHERAL VASCULAR DISEASE; PILOT STUDY; PREDICTIVE VALUE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; PROTEIN URINE LEVEL; DIABETIC NEPHROPATHIES; FOLLOW UP; GLOMERULUS FILTRATION RATE; METABOLISM; MIDDLE AGED; PATHOPHYSIOLOGY; PHYSIOLOGY; PREVALENCE; PROGNOSIS; RENAL INSUFFICIENCY, CHRONIC; UNITED STATES;

AGED; BIOLOGICAL MARKERS; DIABETIC NEPHROPATHIES; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; GLOMERULAR FILTRATION RATE; HUMANS; MALE; MIDDLE AGED; PILOT PROJECTS; PREVALENCE; PROGNOSIS; PROSPECTIVE STUDIES; PROTEINS; RENAL INSUFFICIENCY, CHRONIC; UNITED STATES;

EID: 84928701395     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfu255     Document Type: Article

References (23)

1. de Boer IH, Rue TC, Hall YN et al. Temporal trends in the prevalence of diabetic kidney disease in the United States. JAMA 2011; 305: 2532-2539
2. Afkarian M, Sachs MC, Kestenbaum B et al. Kidney disease and increased mortality risk in type 2 diabetes. J Am Soc Nephrol 2013; 24: 302-308
3. Debella YT, Giduma HD, Light RP et al. Chronic kidney disease as a coronary disease equivalent-a comparison with diabetes over a decade. Clin J Am Soc Nephrol 2011; 6: 1385-1392
4. Vupputuri S, Kimes TM, Calloway MO et al. The economic burden of progressive chronic kidney disease among patients with type 2 diabetes. J Diabetes Complications 2014; 28: 10-16
5. Foley RN, Collins AJ. The growing economic burden of diabetic kidney disease. Curr Diab Rep 2009; 9: 460-465
6. Keane WF, Brenner BM, de Zeeuw D et al. The risk of developing endstage renal disease in patients with type 2 diabetes and nephropathy: the RENAAL study. Kidney Int 2003; 63: 1499-1507
7. Bakris GL, Sarafidis PA, Weir MR et al. Renal outcomes with different fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): a prespecified secondary analysis of a randomised controlled trial. Lancet 2010; 375: 1173-1181
8. Chaudhary K, Phadke G, Nistala R et al. The emerging role of biomarkers in diabetic and hypertensive chronic kidney disease. Curr Diab Rep 2010; 10: 37-42
9. Fassett RG, Venuthurupalli SK, Gobe GC et al. Biomarkers in chronic kidney disease: a review. Kidney Int 2011; 80: 806-821
10. Lewis EJ, Hunsicker LG, Bain RP et al. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med 1993; 329: 1456-1462
11. Lewis EJ, Hunsicker LG, Clarke WR et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001; 345: 851-860
12. Brenner BM, Cooper ME, de Zeeuw D et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345: 861-869
13. Li L, Astor BC, Lewis J et al. Longitudinal progression trajectory of GFR among patients with CKD. Am J Kidney Dis 2012; 59: 504-512
14. Keller C, Katz R, Sarnak MJ et al. Inflammatory biomarkers and decline in kidney function in the elderly: the Cardiovascular Health Study. Nephrol Dial Transplant 2010; 25: 119-124
15. Silver J, Naveh-Many T. FGF-23 and secondary hyperparathyroidism in chronic kidney disease. Nat Rev Nephrol 2013; 9: 641-649
16. Fliser D, Kollerits B, Neyer U et al. Fibroblast growth factor 23 (FGF23) predicts progression of chronic kidney disease: the Mild to Moderate Kidney Disease (MMKD) Study. J Am Soc Nephrol 2007; 18: 2600-2608
17. Lee JE, Gohda T, Walker WH et al. Risk of ESRD and all cause mortality in type 2 diabetes according to circulating levels of FGF-23 and TNFR1. PLoS One 2013; 8: e58007
18. Agarwal R, Bunaye Z, Bekele DM et al. Competing risk factor analysis of end-stage renal disease and mortality in chronic kidney disease. Am J Nephrol 2008; 28: 569-575
19. Ferrara N. Vascular endothelial growth factor: basic science and clinical progress. Endocr Rev 2004; 25: 581-611
20. Hohenstein B, Hausknecht B, Boehmer K et al. Local VEGF activity but not VEGF expression is tightly regulated during diabetic nephropathy in man. Kidney Int 2006; 69: 1654-1661
21. Liu E, Morimoto M, Kitajima S et al. Increased expression of vascular endothelial growth factor in kidney leads to progressive impairment of glomerular functions. J Am Soc Nephrol 2007; 18: 2094-2104
22. Warren CM, Ziyad S, Briot A et al. A ligand-independent VEGFR2 signaling pathway limits angiogenic responses in diabetes. Sci Signal 2014; 7: 1-12
23. Niewczas MA, Gohda T, Skupien J et al. Circulating TNF receptors 1 and 2 predict ESRD in type 2 diabetes. J Am Soc Nephrol 2012; 23: 507-515